No decision from EU drug regulator yet on Wegovy label expansion
LONDON (Reuters) -The EU's drug regulator said on Friday it would continue to review whether Novo Nordisk's popular weight-loss drug Wegovy could also be used in some cases to reduce the risk of strokes and heart attacks. The expert panel assessing Novo's request to include certain heart benefits in the product's label did not adopt an opinion, a spokesperson for the regulator said. "The application is still under review and we cannot speculate on when it will conclude," he added.
Source: yahoo.com
